<DOC>
	<DOCNO>NCT01754740</DOCNO>
	<brief_summary>Objectives : evaluate xerostomia salivary flow patient burn mouth syndrome ( BMS ) treat amitriptyline use antixerostomic topical medication . Methods : In case-control double-blinded study , enrol 38 patient BMS diagnose accord ( IASP ) . The subject randomly divide two group : Study Group : 19 patient receive topical medication urea 10 % Control Group : 19 patient receive placebo apply oral cavity 3-4 time per day , three month . The patient evaluate treatment . Finally , data statistically analyze . It know BMS eventually associate reduced salivary flow ( Cho et al.,2010 ; Kho et al. , 2010 ; Marino et al. , 2010 ) abnormal salivary composition ( increase concentration K+ , Na+ , Cl- , Ca+2 , IgA , amylase ) ( Patton et al. , 2007 ) . Even absence hyposalivation , patient may complain xerostomia dry mouth ( Cho et al.,2010 ; Kho et al. , 2010 ; Marino et al. , 2010 ; Thomson , 2005 ) . These patient also several sensory loss even taste smell function , recently describe ( Siqueira et al. , 2006a ; Siqueira et al. , 2006b ; Siviero et al. , 2011 ) .</brief_summary>
	<brief_title>The Role Xerostomia Burning Mouth Syndrome : Case - Control Study</brief_title>
	<detailed_description>Materials Methods In case-control double-blinded study , enrol 38 patient BMS diagnose accord International Association Study Pain ( IASP ) ( 17 ) , follow Craniofacial Pain Clinic Hospital das Clinicas , School Medicine University Sao Paulo . All subject inform purpose study , sign informed consent . The protocol approve local Ethics Committee . No patient hyposalivation moment diagnosis quantitative evaluation . All patient treat 25mg-50mg amitriptyline within last three month . They underwent laboratory test careful exam exclude cause burn mouth ( 10 ) . The exclusion criterion facial pain syndrome , cause abnormal salivation , neuropathy primary disease associate burn mouth , inability answer question / test The subject randomly divide two group : 1 . Study Group : 19 patient receive topical medication urea 10 % applied oral cavity 3-4 time per day , three month . 2 . Control Group : 19 patient receive placebo ( 5 % sodium carboxymethylcellulose , 0.15 % methyl paraben 10 % glycerol distilled water qsp 100g ) apply oral cavity 3-4 time per day , three month . The patient evaluate treatment follow instrument : 1 . EDOF-HC protocol ( Orofacial Pain Clinic - Hospital da Clinicas ) : standardize orofacial pain questionnaire detail : 1 ) chief complaint , 2 ) general pain characteristic ( location , quality , duration , pain relief , pain trigger ) , 3 ) headache and/or body pain complaint , 4 ) patient 's medical history co-morbidities ( 18,19 ) ; 2 . Xerostomia questionnaire ( 20 ) ; 3 . Quantitative sensory testing . All subject underwent standardize protocol quantitative sensory testing ( QST ) ( 21 ) consist twelve test group follow : - salivary flow ; gustative olfactory threshold ; - thermal detection threshold cold warm sensation ; - mechanical detection threshold touch , vibration electrical perception ; - mechanical pain sensitivity include superficial deep pain threshold ; - electric pain threshold teeth . - corneal reflex .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<mesh_term>Burns</mesh_term>
	<mesh_term>Burning Mouth Syndrome</mesh_term>
	<criteria>All patient treat 25mg50mg amitriptyline within last three month . They underwent laboratory test careful exam exclude cause burn mouth facial pain syndrome , cause abnormal salivation , neuropathy primary disease associate burn mouth , inability answer question / test</criteria>
	<gender>All</gender>
	<minimum_age>37 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Xerostomia , Salivary flow , Burning Mouth Syndrome .</keyword>
</DOC>